Research conducted by Griffith University and Melbourne-based company Paradigm Biopharmaceuticals Limited has uncovered a potential new therapeutic treatment for the global battle against mosquito-borne alphavirus infections, including the debilitating Ross River Virus (RRV) and Chikungunya Virus (CHIKV).
↧